Nuwellis, Inc. Common Stock (NUWE) is a publicly traded ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector company. As of May 21, 2026, NUWE trades at $0.98 with a market cap of $2.58M and a P/E ratio of -0.04. NUWE moved +0.00% today. Year to date, NUWE is -49.26%; over the trailing twelve months it is -97.54%. Its 52-week range spans $0.90 to $175.98. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces NUWE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nuwellis Plans 510(k) Submission to Expand Aquadex to 5 kg Pediatric Patients: Nuwellis completed an FDA pre-submission 510(k) meeting for Aquadex SmartFlow, targeting label expansion to treat pediatric patients weighing from 5 kg to the current 20 kg threshold. FDA feedback outlined required bench tests, toxicology assessments and pediatric clinical evidence, with a 510(k) submission expected by end-2026.
| Metric | Value |
|---|---|
| Price | $0.98 |
| Market Cap | $2.58M |
| P/E Ratio | -0.04 |
| EPS | $-25.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $175.98 |
| 52-Week Low | $0.90 |
| Volume | 4.87K |
| Avg Volume | 0 |
| Revenue (TTM) | $8.27M |
| Net Income | $-17.52M |
| Gross Margin | 61.96% |
1 analysts cover NUWE: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.